Glenmark has recently launched Remogliflozin - a novel SGLT2 inhibitor- and India is the first country to get access to this innovative drug . Remogliflozin has been studied in 26 clinical trials globally, covering about 2,500 patients from various ethnicities . Phase III clinical trials are the best way to find a new paradigm for treatment and change the way how doctors treat patients. Glenmark invites you for an interactive webinar on 26th June 2019 from 9 pm onwards .
In this webinar, Dr. Uday Jadhav and Dr. Mala Dharmaligum will talk about the "Indian Experience Of Remogliflozin - Phase III Clinical Study". We invite you to submit your questions which will be answered by the speakers at the end of the session.
